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Introduction
Stereotactic body radiation therapy (SBRT) is established 
for the management of certain extracranial cancers, most 
notably those in the lung, in which ablative dose can safely 
be delivered and achieve excellent long-term local control 
(LC) (1). SBRT is not feasible for all extracranial tumors, 
however, because of suboptimal soft tissue visualization 
on pre-treatment computerized tomography (CT) and the 
proximity of normal organs such as the bowel. 
Daily image guidance using magnetic resonance (MR) 
has been available for several years at a limited although 
growing number of centers worldwide (2). MR-guided 
radiation therapy (MRgRT) offers several important 
advantages over CT-based image guidance that allows for 
safe tumor dose escalation while also better sparing normal 
organs, and thus may achieve a more favorable therapeutic 
ratio.
We present the following case in accordance with the 
CARE reporting checklist (available at http://dx.doi.
org/10.21037/tro-20-37).
Case report
This is the case of a 49-year-old man with no significant 
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past medical or surgical history who in January 2015 
developed hematuria and underwent a workup including 
cystoscopy and CT scans that revealed a mass in the bladder 
with enlarged pelvic lymph nodes. Bladder biopsy was 
positive for invasive high-grade urothelial carcinoma. He 
underwent open radical cystectomy and prostatectomy with 
bilateral pelvic lymph node dissection and ileal neobladder 
urinary diversion in February 2015 for a 4.3 cm, pT3bN2, 
invasive high-grade urothelial carcinoma of the bladder 
with 2 involved lymph nodes out of 12. Surgical margins 
were negative. 
Restaging CT scans several years later in May 2017 
revealed a 3.7 cm × 2.1 cm right adrenal mass inseparable 
from the right diaphragmatic crus that was consistent 
with distant metastasis. There was no evidence of disease 
recurrence at the primary site of disease in the pelvis or 
elsewhere. 
He initiated treatment with cisplatin and gemcitabine 
in June 2017 for this metachronous OM lesion. CT scans 
in August 2017 showed that although the right adrenal 
mass was stable two lymph nodes in the central root of the 
mesentery were enlarging and suspicious for metastatic 
disease. After receiving 7 cycles of cisplatin and gemcitabine, 
CT scans in April 2018 showed that the right adrenal mass 
had increased to 3.4 cm and the mesenteric lymph nodes 
had increased to 3.1 cm and 1.6 cm, respectively. There 
were no new lesions elsewhere. Cisplatin and gemcitabine 
were discontinued and he was started on atezolizumab.
He began the first cycle of atezolizumab in May 2018 
and CT scans approximately 6 months later demonstrated 
complete resolution of the right adrenal metastasis while the 
mesenteric lymph nodes were stable. His disease remained 
well controlled for an additional year until there was again 
enlargement of the mesenteric lymph nodes to 5.9 and 
1.6 cm, respectively, after 22 cycles of atezolizumab. There 
were no additional sites of progression.
Because the mesenteric lymph nodes were the only site 
of metastatic disease for an extended period of time the 
multidisciplinary tumor board recommended ablative MR-
guided SBRT, which was delivered in late August 2019 on 
the ViewRay MRIdian Linac (ViewRay, Inc., Oakwood 
Village, OH). The MRIdian Linac utilizes an onboard 
0.35 T MR scanner and step-and-shoot radiation delivery. 
Simulation and pre-treatment MRI scans were obtained 
on the treatment machine using a True Fast Imaging with 
Steady State Free Precession (TRUFISP) sequence without 
contrast. An isotropic 3 mm setup margin was placed on the 
gross tumor volume (GTV) to define the planning target 
volume (PTV). Elective nodal regions were not treated 
given the small bowel surrounding the GTV. The GTV 
was 92.9 cc while the PTV was 131.2 cc. Because treatment 
was delivered using a coached mid-inspiration breath hold 
technique, there was no internal target volume (ITV). The 
prescription dose was 50 Gy in 5 consecutive fractions; 
the biologically equivalent dose (BED10) was 100 Gy. An 
intentional hotspot of at least 120% of the prescription 
dose was delivered to as much of the GTV as possible 
while respecting normal organ constraints that included 
the following: small bowel (V35 <0.5 cc; V40 <0.03 cc), 
large bowel (V38 <0.5 cc; V43 <0.03 cc), combined 
kidneys (mean <10 Gy), liver (mean <10 Gy), cauda equina 
(V20 <0.5 cc). A 3 mm planning organ at risk (PRV) margin 
was uniformly expanded around the small bowel and used 
as an optimization structure, with the priority being to meet 
the normal organ constraints and the secondary goal being 
to maximize target volume coverage by the prescription 
dose. The prescription isodose line covered 72.6% of the 
PTV and 83.4% of the GTV. The mean and maximum 
dose to the GTV was 53.6 and 68.6 Gy, respectively.  The 
treatment plan used 13 inversely optimized beams with a 
total of 38 segments. 
On each treatment day a volumetric MR TRUFISP scan 
was acquired in breath hold over 25 seconds (17 seconds is 
another option on the MRIdian Linac). Rigid registration 
of the target volumes and deformable registration of the 
normal organs was performed. The contours were then 
modified to reflect the current day’s anatomy; the normal 
organs were recontoured within 3 cm from the periphery 
of the PTV. The predicted target volume and normal 
organ doses using the current day’s anatomy and original 
treatment plan were evaluated. For each of the 5 fractions 
the predicted small bowel constraint was violated so the 
original plan (Figure 1A) was not used, but rather each 
fraction was reoptimized (Figure 1B,C,D,E,F) while the 
patient remained in treatment position and treatment was 
delivered using the new plan. This allowed all normal 
organ constraints to be satisfied while providing excellent 
dose coverage of the targeted lymph nodes. Continuous 
intrafraction motion was assessed in the sagittal plane 
throughout treatment delivery at a rate of 4 frames per 
second. Treatment was automatically paused if the at least 
5% of the target position extended outside of a 3 mm 
threshold boundary; treatment resumed automatically when 
the target returned to within the defined threshold. The 
median time across all 5 fractions from the patient entering 
the treatment room to treatment delivery completion was 
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Figure 1 Isodose lines from the original treatment plan (A) compared to each daily fraction (B-F) that underwent online adaptive replanning 
due to a significant interfraction change in bowel positioning. The adapted plans ensured all normal organ dose constraints were met; target 
coverage varied depending on the current day’s anatomy although most of the target received the prescribed dose for each fraction. 
A B C
D E F
65 minutes, including time for initial positioning and online 
adaptive replanning. The median treatment delivery time in 
breath hold was 16 minutes. 
The patient tolerated treatment very well and was able 
to complete MR-guided SBRT within 5 consecutive days 
as intended. He did not have severe toxicity and only 
experienced mild diarrhea and bloating.
CT scans in September 2019 demonstrated a reduction in 
the size of the treated mesenteric lesions to 2.3 and 1.2 cm, 
respectively (Figure 2A,B). Two months later there was 
continued regression of the treated mesenteric lymph nodes 
to 1.8 and 1.2 cm, respectively (Figure 2C).
He remained under close observation until a CT scan 
in March 2020 demonstrated progression of disease within 
the right adrenal gland and an upper abdominal mesenteric 
lymph node that was not previously treated with RT. The 
previously treated mesenteric lymph nodes continued to 
decrease in size, measuring 1.3 and 1 cm, respectively. 
Because of disease progression the patient was started on 
weekly paclitaxel, with the potential for additional MR-
guided SBRT to be delivered to those sites pending review 
of treatment response on upcoming restaging scans. A 
timeline of his treatment course is summarized in Table 1.
Written informed consent was obtained from the patient 
for publication of this case report and any accompanying 
images. A copy of the written consent is available for review 
by the Editor-in-Chief of this journal.
Discussion
Radiation therapy (RT) for patients with distant metastasis 
has historically been limited to low dose palliation of 
symptoms such as pain or bleeding. However, dose 
escalated RT for OM disease (typically defined as 1–5 
metastatic lesions) has received substantial attention after 
multiple randomized phase 2 trials demonstrated profound 
improvements in long-term progression free survival (PFS) 
and even potentially overall survival (OS) with the use of 
SBRT and chemotherapy versus chemotherapy alone (3-5). 
These trials included several different cancer types including 
breast, lung, and colorectal. Most recently, a phase 2 trial 
of OM prostate cancer patients showed that the SBRT arm 
achieved significantly improved PFS and enhanced systemic 
immune response compared to those randomized to 
observation (6). There may be a benefit of SBRT for other 
OM cancers including those of the bladder (7). 
Despite increasing enthusiasm for SBRT in the 
management of OM disease, questions remain about ideal 
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Figure 2 Oligometastatic mesenteric lymph nodes (arrow) that had progressed on systemic therapy prior to magnetic resonance-guided 
stereotactic body radiation therapy (A). Progressive radiographic response was observed 4 weeks (B) and 12 weeks (C) after ablation. The 
patient had no significant toxicity despite small bowel (star) abutting the target lesions. 
A
B
C
patient selection and the optimal therapeutic approach (8). 
The aforementioned studies used a spectrum of radiation 
dose fractionation schedules, some being ablative (e.g., 
BED10 ≥100 Gy) while others were non-ablative, largely 
dependent on the anatomic location of the target lesion with 
respect to normal organs. While lesions such as those in the 
peripheral lung are excellent candidates to receive ablative 
dose in 5 or fewer fractions others such as abdominal LNs 
have historically not been because there is a considerable 
risk of severe toxicity due to the proximity of radiosensitive 
organs (e.g., bowel) (9). For example, Augugliaro et al. 
published a retrospective analysis of 13 OM transitional cell 
bladder cancer patients who received RT predominantly 
to recurrent abdominal or pelvic LNs, most commonly 
prescribed to 25 Gy in 5 fractions (BED10=37.5 Gy) (7). 
This non-ablative dose did not result in serious toxicity 
although restaging imaging after 3 months showed in-field 
progression among 38% of patients.
The emergence of MR-guided SBRT has begun to 
transform the field of radiation oncology (10). Not only 
does MRI offer superior soft tissue imaging over CT, thus 
obviating the need for fiducial marker placement, but MR-
guided radiation therapy devices also provide continuous 
intrafraction imaging of the tumor and surrounding normal 
organs throughout treatment allowing for smaller set up 
margins and ultimately target volumes. Additionally, while 
modifying the treatment plan to account for interfraction 
anatomic changes typically requires several days (when using 
CT guidance offline adaptation), MR-guided devices can 
create a new treatment plan within a few minutes based on 
the current day’s anatomy (online adaptation) that facilitates 
ablative treatment. MR-guided SBRT has resulted in 
encouraging early clinical outcomes for OM disease and 
inoperable primary disease (11-14). Dose escalation using 
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MR-guided SBRT is expected to improve outcomes far 
beyond what is achievable using CT guidance, which is 
especially relevant for patients with OM disease who may 
achieve long-term survival with aggressive management (15). 
Several logistical considerations are pertinent for patients 
to be treated with an MR-LINAC. First, it must be verified 
that there is no physical contraindication for having an 
MRI scan due to implanted metallic objects or devices (i.e., 
prosthetic device, pacemaker). Second, patients must be able 
to tolerate lying in the bore of the MR-LINAC, which is 
more confined than a traditional LINAC. In our experience 
this has not been a major limitation for claustrophobic 
patients with the use of anxiolytic medication. Third, our 
MR-LINAC requires that a breath hold volumetric scan 
be performed for simulation and prior to each delivered 
fraction; this scan is ideally done over 25 seconds to 
achieve the highest image quality although can be done 
in 17 seconds if needed. We have not had a patient who 
was unable to tolerate at least the 17 second breath hold 
scan. Lastly, while we typically treat patients with thoracic 
or abdominal tumors in mid-inspiration breath hold to 
improve duty cycle efficiency, treatment in free breathing 
may be considered although the treatment time likely will 
increase.
Our patient had a remarkable response to MR-guided 
SBRT without having significant adverse effects. Despite his 
OM disease, his prognosis appears to be relatively favorable 
given that he was originally diagnosed with bladder cancer 
over 5 years ago, has not had widespread dissemination of 
his cancer, and now has achieved a remarkable response to 
SBRT. His case is notable because the delivery of ablative 
radiation therapy to mesenteric lymph nodes has not 
before been reported, to the best of our knowledge. Using 
MR guidance we were able to safely prescribe 50 Gy in 
5 fractions (BED10 =100 Gy), which is significantly higher 
than what would typically be prescribed using CT guidance 
due to the tolerance of the small bowel (e.g., 25–35 Gy 
in 5 fractions; BED10 =37.5–59.5 Gy). From the patient’s 
perspective, receiving MR-guided SBRT was a positive 
experience since it was able to not only achieve tumor 
reduction despite progression on prior systemic therapies, 
but also offer him hope that he could still continue 
effectively fighting his disease. He is optimistic that his 
disease will remain controlled with chemotherapy and 
that he potentially might receive additional SBRT to any 
remaining sites of disease.
Table 1 Timeline from events since original diagnosis of bladder cancer
Date Event
January 2015 Diagnosed with invasive high-grade urothelial carcinoma of the bladder
February 2015 Radical cystectomy and prostatectomy, pelvic lymph node dissection (pT3bN2)
May 2017 Diagnosed with right adrenal gland metastasis
June 2017 Began gemcitabine/cisplatin
May 2018 Enlarging right adrenal gland metastasis and mesenteric lymph nodes (1.6 cm, 1.2 cm)
Discontinued gemcitabine/cisplatin and started atezolizumab
November 2018 Complete resolution of right adrenal metastasis
Stable mesenteric lymph nodes (3.1 cm, 1.6 cm)
June 2019 Enlarging mesenteric lymph nodes (5.9 cm, 1.9 cm)
Atezolizumab discontinued after 22 cycles
August 2019 MR-guided SBRT (50 Gy in 5 fractions) delivered to mesenteric lymph nodes
September 2019 Decreasing size of mesenteric lymph nodes (2.3 cm, 1.2 cm)
November 2019 Decreasing size of mesenteric lymph nodes (1.8 cm, 1.2 cm)
March 2020 Decreasing size of mesenteric lymph nodes (1.3 cm, 1.0 cm)
Progression in right adrenal gland and upper abdominal mesenteric lymph node
Began weekly paclitaxel
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The role of SBRT in the paradigm of OM management 
will almost certainly expand moving forward based on 
encouraging initial prospective data and the results of trials 
currently in progress that are expected to show a benefit for 
a wider array of cancer types. In that context, there will also 
likely be an increasing indication for daily MRI guidance as 
a means to optimize the therapeutic ratio of SBRT. Given 
that there is not yet extensive follow up using ablative 
dose with MR guidance, additional evaluation is needed 
to better understand long-term safety and efficacy from 
aggressive dosing regimens such as the one used for this 
patient. As such, a prospective trial is under development 
at our institution to evaluate outcomes of ablative MR-
guided SBRT delivered with online adaptive replanning for 
patients with OM disease.
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